Jump to navigation Jump to search
Clinical data
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass356.44 g/mol

WikiDoc Resources for Methylnaltrexone


Most recent articles on Methylnaltrexone

Most cited articles on Methylnaltrexone

Review articles on Methylnaltrexone

Articles on Methylnaltrexone in N Eng J Med, Lancet, BMJ


Powerpoint slides on Methylnaltrexone

Images of Methylnaltrexone

Photos of Methylnaltrexone

Podcasts & MP3s on Methylnaltrexone

Videos on Methylnaltrexone

Evidence Based Medicine

Cochrane Collaboration on Methylnaltrexone

Bandolier on Methylnaltrexone

TRIP on Methylnaltrexone

Clinical Trials

Ongoing Trials on Methylnaltrexone at Clinical

Trial results on Methylnaltrexone

Clinical Trials on Methylnaltrexone at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Methylnaltrexone

NICE Guidance on Methylnaltrexone


FDA on Methylnaltrexone

CDC on Methylnaltrexone


Books on Methylnaltrexone


Methylnaltrexone in the news

Be alerted to news on Methylnaltrexone

News trends on Methylnaltrexone


Blogs on Methylnaltrexone


Definitions of Methylnaltrexone

Patient Resources / Community

Patient resources on Methylnaltrexone

Discussion groups on Methylnaltrexone

Patient Handouts on Methylnaltrexone

Directions to Hospitals Treating Methylnaltrexone

Risk calculators and risk factors for Methylnaltrexone

Healthcare Provider Resources

Symptoms of Methylnaltrexone

Causes & Risk Factors for Methylnaltrexone

Diagnostic studies for Methylnaltrexone

Treatment of Methylnaltrexone

Continuing Medical Education (CME)

CME Programs on Methylnaltrexone


Methylnaltrexone en Espanol

Methylnaltrexone en Francais


Methylnaltrexone in the Marketplace

Patents on Methylnaltrexone

Experimental / Informatics

List of terms related to Methylnaltrexone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Methylnaltrexone (MTNX) is one of the newer agents of peripherally-acting μ-opioid antagonists that act to reverse some of the side effects of opioid drugs such as constipation without affecting analgesia or precipitating withdrawals. Because it contains a permanently charged tetravalent nitrogen atom, it cannot cross the blood-brain barrier, and so has antagonist effects throughout the body, counteracting effects such as itching and constipation, but without affecting opioid effects in the brain such as analgesia.


In December of 2005, Wyeth and Progenics entered into an exclusive, worldwide agreement for the joint development and commercialization of methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative ileus (POI), a prolonged dysfunction of the gastrointestinal (GI) tract following surgery. Under the terms of the agreement, the companies are collaborating on worldwide development. Wyeth received worldwide rights to commercialize methylnaltrexone, and Progenics retained an option to co-promote the product in the United States. Wyeth will pay Progenics royalties on worldwide sales and co-promotion fees within the United States.

Methylnaltrexone is being developed in subcutaneous and oral forms to treat opioid induced constipation (OIC) and an intravenous form for POI.

Progenics and Wyeth are conducting two global phase 3 clinical trials in POI, targeting an NDA submission in this indication in early 2008. An oral formulation for OIC in patients with chronic pain currently is under development with an anticipated NDA submission in late 2009 or early 2010.


  • Holzer P (2007). "Treatment of opioid-induced gut dysfunction". Expert Opin Investig Drugs. 16 (2): 181–94. PMID 17243938.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>


Template:Pharm-stub Template:WikiDoc Sources